Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation.
Deep remission from induction chemotherapy predicts favorable long-term survivals in early stage extranodal nasal NK/T-cell lymphoma receiving sequential chemotherapy and radiation.
复制标题
诱导化疗的深度缓解预示着接受序贯化疗和放疗的早期结外鼻 NK/T 细胞淋巴瘤的良好长期生存
DOI：
10.18632/aging.204355
复制
发表时间：
2022-11-01
期刊：
影响因子：
5.2
通讯作者：
Zhu, Jun
中科院分区：
文献类型：
--
作者：
Qi, Fei;Zhou, Wenyuan;Xie, Yan;Sun, Yan;Wu, Meng;Chai, Yue;Chen, Bo;Lin, Ningjing;Liu, Weiping;Ding, Ning;Li, Yexiong;Dong, Mei;Song, Yuqin;Zhu, Jun
目的：我们的目的是评估诱导化疗（CT）反应和生存率之间的关系，并探索一种适应于接受一线序贯CT和放疗（RT）的局限性淋巴结NK/T细胞淋巴瘤（NKTCL）的诱导CT反应的治疗策略。研究方法：我们回顾性审查了2010年至2020年在两个独立机构接受一线CT+RT的局限性NKTCL患者的数据（主要队列，n = 203;验证队列，n = 67）。分析诱导后的CT（初始缓解）、RT（最终缓解）和生存期。结果：初治完全缓解（CR）组的CR率（99.1%）明显高于初治完全缓解组（78.7%）（P < 0.001）。与初始部分缓解或无应答相比，初始CR与上级的5年无进展生存率（PFS，90.0% vs. 61.4% vs. 30.8%，P < 0.001）和总生存率（OS，93.5% vs. 70.7% vs. 60.6%，P < 0.001）相关。虽然大多数初始非CR病例在RT后达到最终CR，但与初始CR相比，它们仍有缩短OS的趋势（86.9% vs. 90.6%，P = 0.063）。多因素分析显示，初治未完全缓解的患者复发风险（HR = 4.748，95% CI，2.396-9.407，P < 0.001）和死亡风险（HR = 4.296，95% CI，1.802-10.24，P = 0.001）明显高于初治未完全缓解的患者。此外，对于初始非CR患者（76.7% vs. 54.7%，P = 0.026），总CT周期≥6个的强化治疗显著优于初始CR患者的上级5年OS。结论：诱导CT的深度缓解与接受CT+RT的局部NKTCL的良好生存率相关，在临床实践中可能推荐诱导CT反应适应的个体化治疗策略。
Objective: We aimed to assess the association between induction chemotherapy (CT) response and survivals and to explore an induction CT response-adapted treatment strategy for localized extranodal NK/T-cell lymphoma (NKTCL) receiving first-line sequential CT and radiation (RT). Methods: We retrospectively reviewed the data of patients with localized NKTCL receiving first-line CT+RT from 2010 to 2020 at two independent institutes (primary cohort, n = 203; validation cohort, n = 67). Responses after induction CT (initial response), RT (final response) and survivals were analyzed. Results: Patients with initial complete remission (CR) had higher final CR rate than the others (99.1% vs. 78.7%, P < 0.001). Initial CR was associated with superior 5-year progression-free survival (PFS, 90.0% vs. 61.4% vs. 30.8%, P < 0.001) and overall survival (OS, 93.5% vs. 70.7% vs. 60.6%, P < 0.001), as compared to initial partial remission or non-response. Though majority of cases with initial non-CR achieved final CR after RT, they still had a tendency of shortened OS compared with initial CRs (86.9% vs. 90.6%, P = 0.063). Multivariate analysis demonstrated patients with initial non-CR had higher relapse (HR = 4.748, 95% CI, 2.396–9.407, P < 0.001) and death hazard (HR = 4.296, 95% CI, 1.802–10.24, P = 0.001). Furthermore, more intensive therapy of ≥6 total cycles of CT yielded significantly superior 5-year OS for patients with initial non-CR (76.7% vs. 54.7%, P = 0.026) rather than patients with initial CR. Conclusion: Deep remission from induction CT was associated with favorable survivals in localized NKTCL receiving CT+RT, and an induction CT response-adapted individualized treatment strategy might be recommended in clinical practice.
登录
查看更多内容
影响因子：
2.9
作者：
Haverkos, Bradley M.;Pan, Zenggang;Gru, Alejandro A.;Freud, Aharon G.;Rabinovitch, Rachel;Xu-Welliver, Meng;Otto, Brad;Barrionuevo, Carlos;Baiocchi, Robert A.;Rochford, Rosemary;Porcu, Pierluigi
通讯作者：
Porcu, Pierluigi
影响因子：
5.7
作者：
Ma, Xuejun;Guo, Ye;Guo, Xiaomao
通讯作者：
Guo, Xiaomao
单纯放疗对 I 期结外鼻型 NK/T 细胞淋巴瘤患者具有治愈作用
DOI：
10.1016/j.ijrobp.2010.10.040
发表时间：
2012-04-01
影响因子：
7
作者：
Li, Ye-Xiong;Wang, Hua;Yu, Zi-Hao
通讯作者：
Yu, Zi-Hao
DOI：
10.1016/j.ijrobp.2007.05.073
发表时间：
2008-01-01
影响因子：
7
作者：
Huang, Mei-Juan;Jiang, Yu;Lu, You
通讯作者：
Lu, You
影响因子：
45.3
作者：
Cheson, Bruce D.;Fisher, Richard I.;Lister, T. Andrew
通讯作者：
Lister, T. Andrew